Latest News for PRFX
FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery with patient enrollment expected in the second half of 2026
Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch
TEL AVIV, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced that its DeepSolar business unit will participate in Energy Trading Week Europe 2026, taking place September 24–25, 2026, at the Business Design Centre in London.
New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch
Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRFX.
U.S. House Trading
No House trades found for PRFX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.